Skip to main content
. Author manuscript; available in PMC: 2012 Apr 28.
Published in final edited form as: J Med Chem. 2011 Apr 6;54(8):2668–2679. doi: 10.1021/jm101417n

Figure 3.

Figure 3

Antitumor activity of three active oncrasin-1 analogues, compounds 34, 35, and 50, in lung cancer cell lines. A) Dose-dependent antitumor activity. Four lung cancer cell lines (H460, H157, H1299, and H322) were treated with various concentrations of the compounds ranging from 0.031 μM to 31 μM. Cell viability was determined 3 days after treatment by using sulforhodamine B assays. Control cells were treated with solvent (dimethyl sulfoxide), and their value was set as 1. The values shown are the means from a quadruplicate assay. B) Western blot analysis. Lung cancer cells were treated with the compounds at a concentration of 1 μM for 24 hours. Phosphorylation of the CTD or the largest subunit of RNA polymerase II was determined with H5 pPol II antibody. β-actin was used as the loading control. C, control; T, treatment.